Literature DB >> 19497851

DLX5 (distal-less homeobox 5) promotes tumor cell proliferation by transcriptionally regulating MYC.

Jinfei Xu1, Joseph R Testa.   

Abstract

The human DLX homeobox genes, which are related to Dll (Drosophila distal-less gene), encode transcription factors that are expressed primarily in embryonic development. Recently, DLX5 was reported to act as an oncogene in lymphomas and lung cancers, although the mechanism is not known. The identification of target genes of DLX5 can facilitate our understanding of oncogenic mechanisms driven by overexpression of DLX5. The MYC oncogene is aberrantly expressed in many human cancers and regulates transcription of numerous target genes involved in tumorigenesis. Here we demonstrate by luciferase assay that the MYC promoter is specifically activated by overexpression of DLX5 and that two DLX5 binding sites in the MYC promoter are important for transcriptional activation of MYC. We also show that DLX5 binds to the MYC promoter both in vitro and in vivo and that transfection of a DLX5 expression plasmid promotes the expression of MYC in a dose-dependent manner in mammalian cells. Furthermore, overexpression of DLX5 results in increased cell proliferation by up-regulating MYC. Knockdown of DLX5 in lung cancer cells overexpressing DLX5 resulted in decreased expression of MYC and reduced cell proliferation, which was rescued by overexpression of MYC. Because DLX5 has a restricted pattern of expression in adult tissues, it may serve as a potential therapeutic target for the treatment of cancers that overexpress DLX5.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19497851      PMCID: PMC2742824          DOI: 10.1074/jbc.M109.021477

Source DB:  PubMed          Journal:  J Biol Chem        ISSN: 0021-9258            Impact factor:   5.157


  40 in total

1.  Identification of a homeodomain binding element in the bone sialoprotein gene promoter that is required for its osteoblast-selective expression.

Authors:  M D Benson; J L Bargeon; G Xiao; P E Thomas; A Kim; Y Cui; R T Franceschi
Journal:  J Biol Chem       Date:  2000-05-05       Impact factor: 5.157

2.  Expressing the human genome.

Authors:  R Tupler; G Perini; M R Green
Journal:  Nature       Date:  2001-02-15       Impact factor: 49.962

3.  Small-molecule c-Myc inhibitor, 10058-F4, inhibits proliferation, downregulates human telomerase reverse transcriptase and enhances chemosensitivity in human hepatocellular carcinoma cells.

Authors:  Che-Pin Lin; Jean-Dean Liu; Jyh-Ming Chow; Chien-Ru Liu; Hsingjin Eugene Liu
Journal:  Anticancer Drugs       Date:  2007-02       Impact factor: 2.248

Review 4.  Dlx homeobox gene control of mammalian limb and craniofacial development.

Authors:  Petra Kraus; Thomas Lufkin
Journal:  Am J Med Genet A       Date:  2006-07-01       Impact factor: 2.802

Review 5.  Ovarian cancer: homeobox genes, autocrine/paracrine growth, and kinase signaling.

Authors:  B T Hennessy; G B Mills
Journal:  Int J Biochem Cell Biol       Date:  2006-02-21       Impact factor: 5.085

6.  A small-molecule c-Myc inhibitor, 10058-F4, induces cell-cycle arrest, apoptosis, and myeloid differentiation of human acute myeloid leukemia.

Authors:  Ming-Jer Huang; Yuan-chih Cheng; Chien-Ru Liu; Shufan Lin; H Eugene Liu
Journal:  Exp Hematol       Date:  2006-11       Impact factor: 3.084

7.  Activation of placenta-specific transcription factor distal-less homeobox 5 predicts clinical outcome in primary lung cancer patients.

Authors:  Tatsuya Kato; Nagato Sato; Atsushi Takano; Masaki Miyamoto; Hitoshi Nishimura; Eiju Tsuchiya; Satoshi Kondo; Yusuke Nakamura; Yataro Daigo
Journal:  Clin Cancer Res       Date:  2008-04-15       Impact factor: 12.531

8.  A novel recurrent chromosomal inversion implicates the homeobox gene Dlx5 in T-cell lymphomas from Lck-Akt2 transgenic mice.

Authors:  Yinfei Tan; Roman A Timakhov; Mamta Rao; Deborah A Altomare; Jinfei Xu; Zemin Liu; Qingshen Gao; Suresh C Jhanwar; Antonio Di Cristofano; David L Wiest; Janice E Knepper; Joseph R Testa
Journal:  Cancer Res       Date:  2008-03-01       Impact factor: 12.701

9.  Modelling Myc inhibition as a cancer therapy.

Authors:  Laura Soucek; Jonathan Whitfield; Carla P Martins; Andrew J Finch; Daniel J Murphy; Nicole M Sodir; Anthony N Karnezis; Lamorna Brown Swigart; Sergio Nasi; Gerard I Evan
Journal:  Nature       Date:  2008-08-17       Impact factor: 49.962

10.  Abnormal urethra formation in mouse models of split-hand/split-foot malformation type 1 and type 4.

Authors:  Kentaro Suzuki; Ryuma Haraguchi; Tsutomu Ogata; Ottavia Barbieri; Olinda Alegria; Maxence Vieux-Rochas; Naomi Nakagata; Masataka Ito; Alea A Mills; Takeshi Kurita; Giovanni Levi; Gen Yamada
Journal:  Eur J Hum Genet       Date:  2007-09-19       Impact factor: 4.246

View more
  19 in total

1.  Homeobox Gene Deregulation: Impact on the Hallmarks of Cancer.

Authors:  Dhwani Haria; Honami Naora
Journal:  Cancer Hallm       Date:  2013-09-01

2.  Adaptation of ovarian cancer cells to the peritoneal environment: Multiple mechanisms of the developmental patterning gene HOXA9.

Authors:  Song Yi Ko; Honami Naora
Journal:  Cancer Cell Microenviron       Date:  2014-11-13

3.  Exome sequencing reveals a heterozygous DLX5 mutation in a Chinese family with autosomal-dominant split-hand/foot malformation.

Authors:  Xue Wang; Qian Xin; Lin Li; Jiangxia Li; Changwu Zhang; Rongfang Qiu; Chenmin Qian; Hailing Zhao; Yongchao Liu; Shan Shan; Jie Dang; Xianli Bian; Changshun Shao; Yaoqin Gong; Qiji Liu
Journal:  Eur J Hum Genet       Date:  2014-02-05       Impact factor: 4.246

4.  Co-targeting of Akt and Myc inhibits viability of lymphoma cells from Lck-Dlx5 mice.

Authors:  Yinfei Tan; Eleonora Sementino; Jianming Pei; Yuwaraj Kadariya; Timothy K Ito; Joseph R Testa
Journal:  Cancer Biol Ther       Date:  2015-03-20       Impact factor: 4.742

5.  GSK690693 delays tumor onset and progression in genetically defined mouse models expressing activated Akt.

Authors:  Deborah A Altomare; Lili Zhang; Jing Deng; Antonio Di Cristofano; Andres J Klein-Szanto; Rakesh Kumar; Joseph R Testa
Journal:  Clin Cancer Res       Date:  2010-01-15       Impact factor: 12.531

6.  Increased copy number of the DLX4 homeobox gene in breast axillary lymph node metastasis.

Authors:  Clarissa Torresan; Márcia M C Oliveira; Silma R F Pereira; Enilze M S F Ribeiro; Catalin Marian; Yuriy Gusev; Rubens S Lima; Cicero A Urban; Patricia E Berg; Bassem R Haddad; Iglenir J Cavalli; Luciane R Cavalli
Journal:  Cancer Genet       Date:  2014-05-02

7.  DLX5 promotes osteosarcoma progression via activation of the NOTCH signaling pathway.

Authors:  Xiaojing Zhang; Huiqin Bian; Wei Wei; Qian Wang; Jinnan Chen; Ruoxuan Hei; Chen Chen; Xuan Wu; Haochun Yuan; Junxia Gu; Yaojuan Lu; Cheguo Cai; Qiping Zheng
Journal:  Am J Cancer Res       Date:  2021-06-15       Impact factor: 6.166

8.  Dlx5 Homeodomain:DNA Complex: Structure, Binding and Effect of Mutations Related to Split Hand and Foot Malformation Syndrome.

Authors:  Andrew Proudfoot; Herbert L Axelrod; Michael Geralt; Robert J Fletterick; Fumiaki Yumoto; Ashley M Deacon; Marc-André Elsliger; Ian A Wilson; Kurt Wüthrich; Pedro Serrano
Journal:  J Mol Biol       Date:  2016-01-29       Impact factor: 5.469

9.  Homeobox gene Dlx-2 is implicated in metabolic stress-induced necrosis.

Authors:  Su Yeon Lee; Hyun Min Jeon; Cho Hee Kim; Min Kyung Ju; Hye Sun Bae; Hye Gyeong Park; Sung-Chul Lim; Song Iy Han; Ho Sung Kang
Journal:  Mol Cancer       Date:  2011-09-14       Impact factor: 27.401

10.  Transcription Factor DLX5 As a New Target for Promising Antitumor Agents.

Authors:  R A Timakhov; P O Fedichev; A A Vinnik; J R Testa; O O Favorova
Journal:  Acta Naturae       Date:  2011-07       Impact factor: 1.845

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.